GlaxoSmithKline CEO packs his bags for March 2017 exit
It's official: GlaxoSmithKline CEO Andrew Witty is moving on. At the helm of the U.K.-based drugmaker since 2008, Witty will step down in March 2017, clearing the way for a new captain to chart a new course.
Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too
Some of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.
GSK's CEO says it's 'difficult to understand how company is doing'
GlaxoSmithKline's CEO Andrew Witty, who has been accused by major investors of "not doing a very good job" and is in the crosshairs of hedge funds, said in a recent interview in India that it is "difficult to understand how the company is doing because so much has changed."
Glaxo CEO: Consumer health can stand on its own, but don't expect a quick spinoff
Lately, GlaxoSmithKline CEO Andrew Witty has seemed open to splitting off the industry-leading consumer health joint venture he formed with Novartis last year. But let Witty be clear: It likely won't happen for a while.
GSK chief Witty opens up to spinoff talk, with consumer health an obvious choice
GlaxoSmithKline CEO Andrew Witty may be coming around on a breakup. At the J.P. Morgan Healthcare Conference, Witty said he's open to the idea and pegged his consumer health joint venture with Novartis as a possible option.
Witty insists GSK's safe approach, backed by innovative pipeline, is the way to success
GlaxoSmithKline CEO Andrew Witty continues to take heat for moving the U.K. drugmaker heavier into low-margin areas like consumer health and vaccines. But he continues to insist he has it on the right track, that Glaxo has plenty of new drugs on the way that will be first-in-class and sidestep the high price backlash that some competitors are facing.
Investors: GSK chief Witty is safe for now, but one more strike and he's out
As GlaxoSmithKline charts a new course to return to growth, investors are willing to give CEO Andrew Witty some time to see it through.
GSK chief sees cheap money spurring 'poor choices' in pharma M&A;
As pharma companies jump left and right at dealmaking opportunities, GlaxoSmithKline CEO Andrew Witty is scratching his head.
Analysts are souring fast on GlaxoSmithKline's defensive market crouch
Whenever a prominent analyst like Tim Anderson at Bernstein pens a review of a struggling Big Pharma company that asks the question if all hope is lost, you know it will be a painful read for any remaining true believers. GlaxoSmithKline and its embattled CEO Andrew Witty came in for that treatment a few days ago. And even if Anderson's answer was a qualified no, you can hear the clock ticking as the market waits for some kind of sign that there's a coherent plan taking shape to move forward decisively.
Glaxo plants a flag in Singapore with CEO Witty on hand
GlaxoSmithKline planted its flag in Singapore to build on a close relationship with the government of the wealthy city-state where CEO Andrew Witty worked and lived earlier in his career with the U.K. drugmaker.